1. Growth arrest specific 6 concentration is increased in the cerebrospinal fluid of patients with Alzheimer's disease
- Author
-
Cristoforo Comi, Elio Scarpini, Pier Paolo Sainaghi, Mario Pirisi, Miryam Carecchio, Federica Alciato, Mattia Bellan, Roberto Cantello, Chiara Fenoglio, Daniela Galimberti, and Franco L. Lombino
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Inflammation ,tau Proteins ,Disease ,Neuroprotection ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,disease progression ,Alzheimer Disease ,Growth arrest ,Internal medicine ,medicine ,Dementia ,Humans ,Inverse correlation ,Aged ,Amyloid beta-Peptides ,business.industry ,General Neuroscience ,General Medicine ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,Peptide Fragments ,Psychiatry and Mental health ,Clinical Psychology ,030104 developmental biology ,inflammation ,Csf biomarkers ,Educational Status ,Intercellular Signaling Peptides and Proteins ,neuroprotection ,Female ,Geriatrics and Gerontology ,medicine.symptom ,business ,Biomarkers ,Disease Progression ,030217 neurology & neurosurgery - Abstract
Growth arrest specific 6 (Gas6) has neurotrophic and neuroinflammatory functions, and may play a role in Alzheimer's disease (AD). In keeping with this hypothesis, we observed that cerebrospinal fluid (CSF) Gas6 is increased in AD patients compared to controls (63 versus 67 subjects; median value 13.3 versus 9.1 ng/ml; p
- Published
- 2016